Role of the complement system in Long COVID - Farztdinov, Vadim; Zühlke, Boris; Sotzny, Franziska; Steinbeis, Fridolin; Seifert, Martina; Kedor, Claudia; Wittke, Kirsten; Tober-Lau, Pinkus; Zoller, Thomas; Textoris-Taube, Kathrin; Ludwig, Daniela; Dierks, Clemens; et al. (medRxiv, 2024)
Long COVID, or Post-Acute COVID Syndrome (PACS), may develop following SARS-CoV-2 infection, posing a substantial burden to society. Recently, PACS has been linked to a persistent activation of the complement system (CS), offering hope for both a diagnostic tool and targeted therapy. However, our findings indicate that, after adjusting proteomics data for age, body mass index and sex imbalances, the evidence of complement system activation disappears. Furthermore, proteomic analysis of two orthogonal cohorts—one addressing PACS following severe acute phase and another after a mild acute phase—fails to support the notion of persistent CS activation. Instead, we identify a proteomic signature indicative of either ongoing infections or sustained immune activation similar to that observed in acute COVID-19, particularly within the mild-PACS cohort.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Ministry of Education and Research (BMBF), as part of the National Research Initiative - Mass Spectrometry in Systems Medicine - (MSCoreSys), under grant agreement number 01EP2201 (to MR) and 16LW0239K (to MM), under Grant 01EP2201 (to CS) as well as the. Weidenhammer-Zoebele Foundation, and the Berlin University Alliance (BUA Link Lab, 501_Massenspektrometrie, 501_Linklab).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The PA-COVID-19 study is a prospective observational study registered with German clinical trials registry (DRKS 00021688) aiming to provide a platform for clinical characterisation of acute and post-acute COVID-19. The study was approved by the ethics committee of Charite - Universitaetsmedizin Berlin (EA2/066/20) and conducted in accordance with the declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.